• Sign In
  • My Marketwire Account
  • Marketwire Resonate
  • News Dashboard 2.0
  • Mediahub
  • Personal Beat
  • Hot Off the Wire
• Register
• Français
• Marketwired Blog
• Careers
• Contact Marketwired

Browse By:

• Industry
  • Aerospace and Defense
  • Agriculture
  • Automotive
  • Chemicals
  • Computers and Software
  • Education and Training
  • Electronics and Semiconductors
  • Energy and Utilities
  • Environment
  • Financial Services
  • Food and Beverage
  • Government
  • Lifestyle and Leisure
  • Manufacturing and Production
  • Media and Entertainment
  • Medical and Healthcare
  • Pharmaceuticals and Biotech
  • Professional Services
  • Real Estate and Construction
  • Retail
  • Sports
  • Telecom
  • Transportation and Logistics
  • Travel and Hospitality
• Topic
  • Associations
  • Bankruptcy
  • Class action
  • Conference calls
  • Dividends
  • Earnings
  • Earnings projections
  • Financing agreements
  • Initial public offerings
  • Investment opinion
  • Management changes
  • Media advisory
  • Mergers and acquisitions
  • Special news events
  • Stock splits
  • Stock/other market news
  • Trade shows
  • Webcasts
• Type
  • News Releases
  • Media Advisories
  • Feature Packs
  • Webcasts
  • Social Media 2.0

News Room: Biotech

Med BioGene Inc. Comments on Market Activity
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 17, 2013) - Med BioGene Inc. (TSX VENTURE:MBI) today, at the request of the Investment Industry Regulatory Organization of Canada (IIROC...(more)
Med BioGene Inc.  
May 17, 2013 22:24 ET
 

 

National Animal Supplement Council Honors Companies for Excellence in Improving the Standards of the Animal Health Supplement Industry and Presents Ben Jones With Lifetime Achievement Award
ST. PETERSBURG, FL--(Marketwired - May 17, 2013) - National Animal Supplement Council (NASC) hosted its 3rd annual awards ceremony on May 16, oceanfront at the TradeWinds Island Grand Resort on...(more)
NASC  
May 17, 2013 16:10 ET
 

 

Confirmation of BioSyent Inc. 2013 AGM Location
TORONTO, ONTARIO--(Marketwired - May 17, 2013) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today announced that certain documents (the Proxy and the VIF) that have been mailed to...(more)
BioSyent Inc.  
May 17, 2013 16:01 ET
 

 

Aeolus Strengthens Board of Directors With Oncology, Government Contracting and Financial Industry Veterans
MISSION VIEJO, CA--(Marketwired - May 17, 2013) -  Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel...(more)
Aeolus Pharmaceuticals  
May 17, 2013 14:19 ET
 

 

Galapagos creates new warrant plan
MECHELEN, BELGIUM--(Marketwired - May 17, 2013) - Galapagos NV (EURONEXT BRUSSELS: GLPG) announced today that its Board of Directors created 648,490 warrants under a new warrant plan for the...(more)
Galapagos NV  
May 17, 2013 12:11 ET
 

 

DHS Holding, Co. Confirms LuckyFoxCasino.com
NASHVILLE, TN--(Marketwired - May 17, 2013) - DHS Holding, Co. (PINKSHEETS: DHSM) has a wholly-owned subsidiary, Lucky Fox Casino, LTD, which operates out of Belize. Lucky Fox Casino, LTD signed...(more)
DHS Holding Co.  
May 17, 2013 11:27 ET
 

 

Immunotec Announces New CEO
VAUDREUIL-DORION, QUÉBEC--(Marketwired - May 17, 2013) - Immunotec Inc. (TSX VENTURE:IMM), a Canadian based company and a leader in the wellness industry ("Immunotec" or the "Company")...(more)
Immunotec Inc.  
May 17, 2013 10:23 ET
 

 

PURE Bioscience Appoints Dave Pfanzelter Chairman of the Board
SAN DIEGO, CA--(Marketwired - May 17, 2013) - PURE Bioscience (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, appointed food industry leader Dave Pfanzelter...(more)
PURE Bioscience, Inc.  
May 17, 2013 09:10 ET
 

 

PURE Bioscience Stock to Begin Trading on the OTCQB Marketplace
SAN DIEGO, CA--(Marketwired - May 17, 2013) - PURE Bioscience (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that its common stock has been...(more)
PURE Bioscience, Inc.  
May 17, 2013 09:05 ET
 

 

Novo Nordisk reports positive results from first phase 3 trial with long-acting factor IX for treatment of haemophilia B
BAGSVAERD, DENMARK--(Marketwired - May 17, 2013) - Novo Nordisk today announced the completion of paradigm™ 2, the first phase 3 trial with a long-acting FIX derivative, N9-GP (glycopegylated...(more)
Novo Nordisk A/S  
May 17, 2013 08:37 ET